These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 1165476)

  • 21. Spectrotypic analysis of antibodies to acetylcholine receptors in experimental autoimmune myasthenia gravis.
    Bionda A; De Baets MH; Tzartos SJ; Lindstrom JM; Weigle WO; Theophilopoulos AN
    Clin Exp Immunol; 1984 Jul; 57(1):41-50. PubMed ID: 6611231
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Inhibition of experimental autoimmune myasthenia gravis by major histocompatibility complex class II competitor peptides results not only in a suppressed but also in an altered immune response.
    Wauben MH; Hoedemaekers AC; Graus YM; Wagenaar JP; van Eden W; de Baets MH
    Eur J Immunol; 1996 Dec; 26(12):2866-75. PubMed ID: 8977279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Specificities of antibody to acetylcholine receptor in rabbits with experimental myasthenia gravis.
    Ueno S; Kang J; Takeuchi H; Takahashi M; Tarui S
    Clin Exp Immunol; 1980 Jul; 41(1):13-8. PubMed ID: 6777100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Specificity of the T cell immune response to acetylcholine receptor in experimental autoimmune myasthenia gravis. Response to subunits and synthetic peptides.
    Fujii Y; Lindstrom J
    J Immunol; 1988 Mar; 140(6):1830-7. PubMed ID: 2450133
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Disruption of the IL-1beta gene diminishes acetylcholine receptor-induced immune responses in a murine model of myasthenia gravis.
    Huang D; Shi FD; Giscombe R; Zhou Y; Ljunggren HG; Lefvert AK
    Eur J Immunol; 2001 Jan; 31(1):225-32. PubMed ID: 11265638
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Passive transfer of experimental myasthenia gravis via antigenic modulation of acetylcholine receptor.
    Loutrari H; Kokla A; Tzartos SJ
    Eur J Immunol; 1992 Sep; 22(9):2449-52. PubMed ID: 1516631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental myasthenia gravis. A murine system.
    Berman PW; Patrick J
    J Exp Med; 1980 Jan; 151(1):204-23. PubMed ID: 7350247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single-fiber electromyography in experimental autoimmune myasthenia gravis.
    Verschuuren JJ; Spaans F; De Baets MH
    Muscle Nerve; 1990 Jun; 13(6):485-92. PubMed ID: 2366822
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lewis rats given antibodies against denatured acetylcholine receptor become resistant to induction of experimental autoimmune myasthenia gravis.
    Krolick KA; Yeh TM; Edlund SA
    Cell Immunol; 1996 Aug; 172(1):10-20. PubMed ID: 8806801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. On the initial trigger of myasthenia gravis and suppression of the disease by antibodies against the MHC peptide region involved in the presentation of a pathogenic T-cell epitope.
    Atassi MZ; Oshima M; Deitiker P
    Crit Rev Immunol; 2001; 21(1-3):1-27. PubMed ID: 11642597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathogenesis of myasthenia gravis as a disorder of acetylcholine receptors.
    Drachman DB; Pestronk A; Stanley EF
    Adv Cytopharmacol; 1979; 3():237-44. PubMed ID: 382787
    [No Abstract]   [Full Text] [Related]  

  • 32. Anti-idiotypic route to anti-acetylcholine receptor antibodies and experimental myasthenia gravis.
    Wassermann NH; Penn AS; Freimuth PI; Treptow N; Wentzel S; Cleveland WL; Erlanger BF
    Proc Natl Acad Sci U S A; 1982 Aug; 79(15):4810-4. PubMed ID: 6181515
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevention of experimental autoimmune myasthenia gravis by manipulation of the immune network with a complementary peptide for the acetylcholine receptor.
    Araga S; LeBoeuf RD; Blalock JE
    Proc Natl Acad Sci U S A; 1993 Sep; 90(18):8747-51. PubMed ID: 8378359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Acetylcholine receptor antibody titer, sensitivity to curare electromyogram and disease severity in myasthenia gravis].
    Chen SM
    Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1991 Jun; 24(3):169-73, 189. PubMed ID: 1889330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental models of myasthenia gravis: lessons in autoimmunity and progress toward better forms of treatment.
    Pachner AR
    Yale J Biol Med; 1987; 60(2):169-77. PubMed ID: 3495075
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral administration of acetylcholine receptor: effects on experimental myasthenia gravis.
    Okumura S; McIntosh K; Drachman DB
    Ann Neurol; 1994 Nov; 36(5):704-13. PubMed ID: 7979216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The limitation of IL-10-exposed dendritic cells in the treatment of experimental autoimmune myasthenia gravis and myasthenia gravis.
    Xiao BG; Duan RS; Zhu WH; Lu CZ
    Cell Immunol; 2006 Jun; 241(2):95-101. PubMed ID: 17005165
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats.
    Zhang GX; Ma CG; Xiao BG; Bakhiet M; Link H; Olsson T
    Eur J Immunol; 1995 May; 25(5):1191-8. PubMed ID: 7774622
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of the anti-acetylcholine receptor response and experimental autoimmune myasthenia gravis by recombinant fragments of the acetylcholine receptor.
    Barchan D; Asher O; Tzartos SJ; Fuchs S; Souroujon MC
    Eur J Immunol; 1998 Feb; 28(2):616-24. PubMed ID: 9521072
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.